Abstract
Introduction and objectives: The use of biologic treatments in patients with psoriasis is traditionally limited in those with a previous history of cancer, due to the potential risk of neoplasm reactivation. There are few published studies on the safety of biological therapies in these patients in real practice. The aim was to evaluate efficacy and safety of biological therapies for psoriasis in patients with previous malignancies in real practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
